

References

This is the reference list to the ACE Clinical Guideline "Chronic kidney disease – delaying progression and reducing cardiovascular complications".

1. Wong LY, Liew AST, Weng WT, et al. Projecting the burden of chronic Kidney Disease in a Developed Country and Its Implications on Public Health. *Int J Nephrol*. 2018;5196285.
2. Liyanage T, Tayama T, Hockham C, et al. Prevalence of chronic kidney disease in Asia: a systematic review and analysis. *BMJ Glob Health*. 2022;7(1):e007525.
3. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. *J Nephrol*. 2014;3(3):99-104.
4. Vallianou N, Mitesh S, Gkogkou A, et al. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? *Curr Cardiol Rev*. 2019;15(1):55-63.
5. Epidemiology & Disease Control Division and Policy, Research and Surveillance Group. National Population Health Survey 2019-2020. Ministry of Health and Health Promotion Board, Singapore; 2020. Available from: www.moh.gov.sg/resources-statistics/reports/national-survey-2019-20 [Accessed 26 October 2023]
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. The Kidney Disease Improving Global Outcomes; 2012.
7. National Institute for Health and Care Excellence (NICE). Chronic kidney disease in adults: assessment and management. London: National Institute for Health and Care Excellence (UK); 2021.
8. Zhang Y, He D, Zhang W, et al. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. *Drugs*. 2020;80(8):797-811.
9. Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. *Am J Kidney Dis*. 2016;67(5):728-741.
10. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*. 2001;345:870-878.
11. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. *Am J Nephrol*. 2000;20(5):373-379.
12. Zhao M, Wang R, Yu Y, et al. Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis. *Front Pharmacol*. 2021;12:638611.
13. NPS MEDICINEWISE. Medicines for chronic kidney disease: A practical guide. Australia: NPS Australia; 2022. Available from: <https://www.nps.org.au/news/medicines-for-chronic-kidney-disease-a-practical-guide>. [Accessed 26 October 2023]
14. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380:2295-2306.
15. Heerspink HJL, Stefansson B, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383:1436-1446.
16. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023;388(2):117-127.
17. Tuttle KR, Levin A, Nangaku M, et al. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. *Diabetes Care*. 2022;45(6):1445-1452.
18. Agarwal R, Filippatos G, Pitt B, et al. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J*. 2022;43(6):474-484.
19. Zhao LM, Zhan ZL, Ning J, et al. Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. *Front Pharmacol*. 2022;12:751496.
20. Bakris GL, Agarwal R, Anker SD. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med*. 2020;383(23):2219-2229.

21. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2021;385:2252-2263.
22. Xi Yan O, Cheng YS. How Can We HALT-CKD In Primary Care? Clinical Care Paths To Manage Chronic Kidney Disease. *SFP*. 2021;47(8):13-18.
23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Clinical Practice Guideline For The Management Of Blood Pressure In Chronic Kidney Disease. 2021.
24. SPRINT Research Group, Wright Jr JJ, Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015;373(22):2103-2116.
25. Voskamp PWM, van Diepen M, Dekker FW, et al. Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients. *Sci Rep*. 2018;8(1):3130.
26. Pontremoli R, Bellizzi V, Bianchi S, et al. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. *J nephrol*. 2020;33(3):417-430.
27. Naderi S, Foody JM. Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review. *Int J Nephrol Renovasc Dis*. 2012;5:165-169.
28. Jankowski J, Floege J, Fliser D, et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. *Circulation*. 2021;143(11):1157-1172.
29. Navarro-Pérez J, Orozco-Beltrán D, Gil-Guillen V, et al. Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. *BMC Cardiovasc Disord* 2018;18:180.
30. MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. *World J Diabetes*. 2017;8(5):172-186.
31. Khoo CM, Deerochanawong C, Chan SP, et al. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. *Diabetes Obes Metab*. 2021;23(2):299-317.
32. Sattar N, Lee MM, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9(10):653-662.
33. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 Diabetes: an updated meta-analysis of eight CVOTs. *Cardiovasc Diabetol*. 2021;20(1):189.
34. Richardson MM, Nolin TD. A decade after the KDOQI CKD guidelines: impact on medication safety. *Am J Kidney Dis*. 2012;60(5):13-15.
35. Evangelidis N, Craig J, Bauman A, et al. Lifestyle behaviour change for preventing the progression of chronic kidney disease: a systematic review. *BMJ Open*. 2019;9(10):e031625.
36. Yan B, Su X, Xu B, et al. Effect of diet protein restriction on progression of chronic kidney disease: A systematic review and meta-analysis. *PLoS One*. 2018;13(11):e0206134.
37. Morris A, Krishnan N, Kimani PK, et al. Effect of Dietary Potassium Restriction on Serum Potassium, Disease Progression, and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *J Ren Nutr*. 2020;30(4):276-285.
38. Picard K, Barreto Silva MI, Mager D, et al. Dietary Potassium Intake and Risk of Chronic Kidney Disease Progression in Predialysis Patients with Chronic Kidney Disease: A Systematic Review. *Adv Nutr*. 2020;11(4):1002-1015.
39. McMahon EJ, Campbell KL, Bauer JD, et al. Altered dietary salt intake for people with chronic kidney disease. *Cochrane Database of Syst Rev*. 2021;6(6):CD010070. doi: 10.1002/14651858.CD010070.pub3.
40. Shi H, Su X, Li C, et al. Effect of a low-salt diet on chronic kidney disease outcomes: a systematic review and meta-analysis. *BMJ Open*. 2022;12(1):e050843.
41. WHO. Sodium intake for adults and children. World Health Organization; 2012. Available from: <https://www.who.int/publications/i/item/9789241504836> [Accessed 26 October 2023]
42. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. KDIGO; 2022.
43. Bovée DM, Visser WJ, Middel I, et al. A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. *J Amer Soc Nephrol*. 2020;31(3):650-662.

44. National Kidney Disease Education Program (NKDEP). Making Sense of CKD: A Concise Guide for Managing Chronic Kidney Disease in the Primary Care Setting. 2014.
45. Society of Infectious Disease (Singapore), the Institute of Infectious Disease and Epidemiology, the College of Family Physicians of Singapore, and the Chapter of Infectious Disease Physicians of the Academy of Medicine of Singapore. Handbook on Adult Vaccination in Singapore 2020. Available from: <http://www.sids.org.sg/publications> [Accessed 26 October 2023].